

**PRIOR AUTHORIZATION REQUEST FORM**

**BRAND ANTIDEPRESSANTS**

Emsam<sup>®</sup>, Fetzima<sup>®</sup>, Trintellix<sup>®</sup>, Viibryd<sup>®</sup>

**For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.**

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Product being requested:**  Emsam<sup>®</sup> (selegiline transdermal system),  Fetzima<sup>®</sup> (levomilnacipran),  Trintellix<sup>®</sup> (vortioxetine),  Viibryd<sup>®</sup> (vilazodone)

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section**

Questions	Yes	No	Comments/Notes
1. Is the member 18 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does the member have a diagnosis of major depressive disorder?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member tried and failed at least one generic selective serotonin reuptake inhibitor (SSRI) (e.g., sertraline, citalopram, fluoxetine, etc.)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Has the member tried and failed at least one generic serotonin norepinephrine reuptake inhibitor (SNRI) (e.g., venlafaxine, duloxetine, etc.)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Has the member tried and failed at least one of the following: <ul style="list-style-type: none"> <li>• mirtazapine</li> <li>• bupropion</li> <li>• any other antidepressant</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>Emsam ONLY:</b>			
1. Does clinical documentation show that the member is unable to swallow or has severe dysphagia preventing member from taking solid oral medications?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**REAUTHORIZATION**

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member had a clinically significant response to therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

3. Does the member show a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

**\*\*Failure to submit clinical documentation to support this request will result in delay and/or denial of the request\*\***

Policy PHARM- 005  
 Origination Date: 01/15/2018  
 Reviewed/Revised Date: 03/25/2020  
 Next Review Date :03/25/2021  
 Current Effective Date: 03/26/2020

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.